cx-072
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT03013491)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- cx-072
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04596150 | Phase 2 | Dec 15, 2020 | CytomX Therapeutics |
| NCT03993379 | Phase 2 | Jul 31, 2019 | CytomX Therapeutics |
| NCT03013491 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2017 | CytomX Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytomX Therapeutics | For profit | 3 | 3 | 1 | 2017 |
1 organizations
Page 1 / 1